- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
First Generic Version of MS Drug Copaxone Approved
After months of anticipation, the FDA has approved a generic version of Copaxone, which means Momenta Pharmaceuticals and Sandoz can now sell a knockoff of a drug that generated more than $3.1 billion in sales in the US last year.
After months of anticipation, the FDA has approved a generic version of Copaxone, a widely used multiple sclerosis drug sold by Teva Pharmaceuticals. The move means that Momenta Pharmaceuticals and the Sandoz unit of Novartis, which have a manufacturing and marketing partnership, can now sell a knockoff of a drug that generated more than $3.1 billion in sales in the US last year.
The approval comes after a protracted effort by Teva to convince the FDA not to endorse a generic version. Over the last few years, Teva filed several so-called citizen’s petitions with the agency and argued that formulating a knockoff would be complicated. “It’s a very complex product and not easy to duplicate,” says Craig Wheeler, the Momenta executive. “But we view this as an endorsement of our technology.”
Read more at Wall Street Journal's Pharmalot blog: http://on.wsj.com/1DT9m5t
Distinguishing Biomarkers Identified in MS Outcomes
March 19th 2024Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
Read More
Choroid Plexus Indicated in MS Pathology
February 9th 2024A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Read More
